Pfizer CEO says Democratic gains unlikely to alter Trump-era MFN pricing agreements

Pfizer chief Albert Bourla told reporters that he does not anticipate any changes to the most‑favored‑nation pricing arrangements that were put in place under the Trump administration, even if the upcoming midterm elections bring more Democrats into Congress.

The MFN deals lock in drug pricing terms for companies that sell to the federal government, and they have been a point of focus for policymakers seeking to control prescription‑drug costs. Bourla said the contracts are binding and not subject to political shifts.

He added that Pfizer will continue to operate under the existing agreements, suggesting stability for the company’s revenue streams and for investors watching the sector for policy risk.